Introduction
Artificial intelligence (AI) is transforming breast cancer detection by enhancing early diagnosis and alleviating radiologist workload, essential for improving patient outcomes and screening efficiency. A recent study, conducted by researchers from Norway and Denmark,…
We developed and evaluated the Digital Platform for Exercise (DPEx): a decentralized, patient-centric approach designed to enhance all aspects of clinical investigation of exercise therapy. DPEx integrated provision of a treadmill with telemedicine and…
Continue Reading
Siemens Healthineers has received FDA Premarket Approval (PMA) for its cutting-edge Mammomat B.brilliant mammography system. This innovative system integrates new 3D image acquisition and reconstruction technology, setting a new standard for breast cancer screening….
Continue Reading
Breast cancer treatment has evolved rapidly over the years, with technological advancements playing a critical role in improving patient outcomes. A groundbreaking study recently presented at the American Society of Radiation Oncology (ASTRO) annual…
Continue Reading
Women in Somerset with breast lumps will be directly referred to a breast diagnostic clinic via the NHS App under a pilot scheme, health secretary Wes Streeting has announced.
Speaking at the Royal College of…
AI biotech company Owkin announced a partnership with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.According to Owkin, BRCA…
Continue Reading
A public-private national project in India has introduced what could be the country’s first comprehensive cancer multi-omics database fifteen years after its founding.The Indian Cancer Genome Atlas (ICGA) focuses on studying cancer biology specific…
Continue Reading
Funding will Support Expanded Commercialization Efforts for PreciseBreast Risk Assessment
PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in…
In this case study, Plexaa, an alumnus company of the Accelerating FemTech programme, shares how their patented supraphysiological preconditioning device, BLOOM43, will ensure positive wound healing outcomes for patients undergoing breast cancer surgery. Overview Out of…
Continue Reading
In this case study, IBEX Innovations, an alumnus company of the Accelerating FemTech programme, shares how their software solution IBEX Bone Health can be integrated into routine breast cancer screening programmes for the early…
Continue Reading
